Skip to main content
Mendus logo

Mendus — Investor Relations & Filings

Ticker · IMMU ISIN · SE0005003654 LEI · 529900AFBGFR7ZB50J95 ST Manufacturing
Open in API
Filings indexed 403 across all filing types
Latest filing 2026-04-17 Annual Report
Country SE Sweden
Listing ST IMMU

About Mendus

https://mendus.com/

Mendus is a clinical-stage company developing immunotherapies to improve long-term survival for cancer patients. The company's primary focus is on preventing tumor recurrence, a leading cause of cancer-related mortality. By leveraging its expertise in allogeneic dendritic cell biology, Mendus designs therapies that stimulate the immune system to build active and long-lasting immunity against residual cancer cells. This approach aims to change the course of cancer treatment by offering durable responses while preserving the patient's quality of life. The company's pipeline is centered on maintenance therapies for various forms of cancer.

Recent filings

Filing Released Lang Actions
Annual Report 2025
Annual Report Classification · 1% confidence The document is titled 'Års- och koncernredovisning 2025' (Annual and Consolidated Report 2025) for the company Mendus. It contains comprehensive financial information, including the Board of Directors' report, financial statements (income statement, balance sheet, cash flow), notes, and an auditor's report. It covers the full fiscal year 2025 and provides detailed business descriptions and financial summaries, which aligns perfectly with the definition of an Annual Report (10-K). FY 2025
2026-04-17 Swedish
Notice of Annual General Meeting in Mendus AB (publ)
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a notice convening the Annual General Meeting, including the agenda, proxy instructions, and Nomination Committee proposals. It is sent to shareholders to inform them and solicit their votes. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-01 English
Kallelse till årsstämma i Mendus AB (publ)
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a press release serving as the official notice (kallelse) to Mendus AB’s 2026 Annual General Meeting. It includes registration instructions, agenda items, proposals from the nomination committee, and voting particulars — all of which are materials sent to shareholders to inform them and solicit their votes. This aligns with the Proxy Solicitation & Information Statement category (PSI).
2026-04-01 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly report for Mendus AB covering the period October-December 2025. It contains detailed financial summaries (income statement, balance sheet data), management's discussion and analysis of clinical trials (ADVANCE II, ALISON, CADENCE, DIVA), and operational updates. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q4 2025
2026-02-11 Swedish
Audit Report / Information 2025
Audit Report / Information Classification · 1% confidence The document is a 'Year-End Report' for 2025, which covers the full financial performance, business activities, and management commentary for the fiscal year. It includes detailed financial tables for Q4 and the full year, a CEO review, and operational updates. This aligns with the definition of an Interim/Quarterly Report (IR) or Annual Report (10-K). Given it is labeled 'Year-End Report' and covers the full year 2025, it functions as the comprehensive annual financial disclosure for the company. Q4 2025
2026-02-11 English
Mendus draws first tranche of the Fenja Capital II A/S loan facility and resolves on a directed issue of warrants to Fenja
Capital/Financing Update Classification · 1% confidence The document is a press release from Mendus AB announcing the drawdown of a loan facility and a directed issue of warrants to Fenja Capital II A/S. This falls under the category of company financing activities, specifically detailing the terms of a loan and the issuance of equity-linked instruments (warrants). According to the provided definitions, 'Capital/Financing Update' (CAP) is the most accurate classification for updates on company fundraising, financing activities, or capital structure changes.
2026-01-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.